Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 22;8(8):CD015196.
doi: 10.1002/14651858.CD015196.pub2.

Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia

Martin Taylor-Rowan  1 , Olga Kraia  1 , Christina Kolliopoulou  1 , Anna H Noel-Storr  2 , Ahmed A Alharthi  3 , Amanda J Cross  4 , Carrie Stewart  5 , Phyo K Myint  6 , Jenny McCleery  7 , Terry J Quinn  1
Affiliations
Meta-Analysis

Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia

Martin Taylor-Rowan et al. Cochrane Database Syst Rev. .

Abstract

Background: Medications with anticholinergic properties are commonly prescribed to older adults with a pre-existing diagnosis of dementia or cognitive impairment. The cumulative anticholinergic effect of all the medications a person takes is referred to as the anticholinergic burden because of its potential to cause adverse effects. It is possible that a high anticholinergic burden may be a risk factor for further cognitive decline or neuropsychiatric disturbances in people with dementia. Neuropsychiatric disturbances are the most frequent complication of dementia that require hospitalisation, accounting for almost half of admissions; hence, identification of modifiable prognostic factors for these outcomes is crucial. There are various scales available to measure anticholinergic burden but agreement between them is often poor.

Objectives: Our primary objective was to assess whether anticholinergic burden, as defined at the level of each individual scale, was a prognostic factor for further cognitive decline or neuropsychiatric disturbances in older adults with pre-existing diagnoses of dementia or cognitive impairment. Our secondary objective was to investigate whether anticholinergic burden was a prognostic factor for other adverse clinical outcomes, including mortality, impaired physical function, and institutionalisation.

Search methods: We searched these databases from inception to 29 November 2021: MEDLINE OvidSP, Embase OvidSP, PsycINFO OvidSP, CINAHL EBSCOhost, and ISI Web of Science Core Collection on ISI Web of Science.

Selection criteria: We included prospective and retrospective longitudinal cohort and case-control observational studies, with a minimum of one-month follow-up, which examined the association between an anticholinergic burden measurement scale and the above stated adverse clinical outcomes, in older adults with pre-existing diagnoses of dementia or cognitive impairment. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion, and undertook data extraction, risk of bias assessment, and GRADE assessment. We summarised risk associations between anticholinergic burden and all clinical outcomes in a narrative fashion. We also evaluated the risk association between anticholinergic burden and mortality using a random-effects meta-analysis. We established adjusted pooled rates for the anticholinergic cognitive burden (ACB) scale; then, as an exploratory analysis, established pooled rates on the prespecified association across scales. MAIN RESULTS: We identified 18 studies that met our inclusion criteria (102,684 older adults). Anticholinergic burden was measured using five distinct measurement scales: 12 studies used the ACB scale; 3 studies used the Anticholinergic Risk Scale (ARS); 1 study used the Anticholinergic Drug Scale (ADS); 1 study used the Anticholinergic Effect on Cognition (AEC) Scale; and 2 studies used a list developed by Tune and Egeli. Risk associations between anticholinergic burden and adverse clinical outcomes were highly heterogenous. Four out of 10 (40%) studies reported a significantly increased risk of greater long-term cognitive decline for participants with an anticholinergic burden compared to participants with no or minimal anticholinergic burden. No studies investigated neuropsychiatric disturbance outcomes. One out of four studies (25%) reported a significant association with reduced physical function for participants with an anticholinergic burden versus participants with no or minimal anticholinergic burden. No study (out of one investigating study) reported a significant association between anticholinergic burden and risk of institutionalisation. Six out of 10 studies (60%) found a significantly increased risk of mortality for those with an anticholinergic burden compared to those with no or minimal anticholinergic burden. Pooled analysis of adjusted mortality hazard ratios (HR) measured anticholinergic burden with the ACB scale, and suggested a significantly increased risk of death for those with a high ACB score relative to those with no or minimal ACB scores (HR 1.153, 95% confidence interval (CI) 1.030 to 1.292; 4 studies, 48,663 participants). An exploratory pooled analysis of adjusted mortality HRs across anticholinergic burden scales also suggested a significantly increased risk of death for those with a high anticholinergic burden (HR 1.102, 95% CI 1.044 to 1.163; 6 studies, 68,381 participants). Overall GRADE evaluation of results found low- or very low-certainty evidence for all outcomes. AUTHORS' CONCLUSIONS: There is low-certainty evidence that older adults with dementia or cognitive impairment who have a significant anticholinergic burden may be at increased risk of death. No firm conclusions can be drawn for risk of accelerated cognitive decline, neuropsychiatric disturbances, decline in physical function, or institutionalisation.

PubMed Disclaimer

Conflict of interest statement

MT: none

TQ: none

JM: none

CS: none

PM: none

AJC: none

OK: none

CK: none

AA: none

Figures

1
1
2
2
Authors' assessment of risk of bias for each domain, for each trial
3
3
Risk of bias for each domain, across studies
4
4
Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, measured by the Anticholinergic Cognitive Burden scale.
5
5
Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, regardless of scale used to measure anticholinergic burden.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD015196

References

References to studies included in this review

Ah 2019 {published data only}
    1. Ah YM, Suh Y, Jun K, Hwang S, Lee JY. Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic & Clinical Pharmacology & Toxicology 2019;124(6):741-8. [PMID: ] - PubMed
Bishara 2020 {published data only}
    1. Bishara D, Perera G, Harwood D, Taylor D, Sauer J, Stewart R, et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry 2020;35(9):1069-77. [DOI: 10.1002/gps.5330] - DOI - PubMed
Bottiggi 2007 {published data only}
    1. Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Schmitt FA. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry 2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354] - DOI - PubMed
Boudreau 2011 {published data only}
    1. Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry 2011;59(11):2069-76. [PMID: ] - PubMed
Cross 2017 {published data only}
    1. Cross AJ, George J, Woodward MC, Ames D, Brodaty H, Wolfe R, Connors MH, Elliott RA. Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis 2017;60(2):349-358. [PMID: ] - PubMed
Dyer 2020 {published data only}
    1. Dyer AH, Murphy C, Segurado R, Lawlor B, Kennelly SP, NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease? The Journals of Gerontology: Series A 2020;75(5):987-94. [PMID: ] - PubMed
Fox 2011 {published data only}
    1. Fox C, Livingston G, Maidment ID, Coulton S, Smithard DG, Boustani M, et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing 2011;40(6):730-5. [PMID: ] - PubMed
Haaksma 2019 {published data only}
    1. Haaksma ML, Rizzuto D, Leoutsakos JS, Marengoni A, Tan ECK, Olde Rikkert MGM, et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association 2019;20(11):1444-50. [PMID: ] - PubMed
Jenraumjit 2020 {published data only}
    1. Jenraumjit R, Chinwong S, Chinwong D, Kanjanarach T, Kshetradat T, Wongpakaran T, et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes 2020;13(1):4. [PMID: ] - PMC - PubMed
Kumpula 2011 {published data only}
    1. Kumpula EK, Bell JS, Soini H, Pitkälä KH. Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology 2011;51(2):256-63. [PMID: ] - PubMed
Landi 2014 {published data only}
    1. Landi F, Dell'Aquila G, Collamati A, Martone AM, Zuliani G, Gasperini B, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association 2014;15(11):825-9. [PMID: ] - PubMed
Lopez‐Matons 2018 {published data only}
    1. López-Matons N, Conill Badell D, Obrero Cusidó G, Gil Saladié D, Padrós Selma J, Martin-López A. Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition) 2018;151(4):141-4. [PMID: ] - PubMed
Lu 2003 {published data only}
    1. Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry 2003;11(4):458-61. [PMID: ] - PubMed
McMichael 2021 {published data only}
    1. McMichael AJ, Zafeiridi E, Ryan M, Cunningham EL, Passmore AP, McGuinness B. Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging & Mental Health 2021;25(8):1475-82. [PMID: ] - PubMed
Porter 2019 {published data only}
    1. Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open 2019;9:e026171. [PMID: ] - PMC - PubMed
Tan 2018 {published data only}
    1. Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease 2018;65(2):589-96. [PMID: ] - PubMed
Trevisan 2021 {published data only}
    1. Trevisan C, Limongi F, Siviero P, Noale M, Cignarella A, Manzato E, et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research 2021;33(1):49-56. [PMID: ] - PubMed
Vetrano 2016 {published data only}
    1. Vetrano DL, La Carpia D, Grande G, Casucci P, Bacelli T, Bernabei R, et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association 2016;17(11):1056-9. [PMID: ] - PubMed

References to studies excluded from this review

Agnoli 1983 {published data only}
    1. Agnoli A, Martucci N, Manna V, Conti L, Fioravanti M. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study. Clinical Neuropharmacology 1983;6(4):311-23. - PubMed
Ang 2015 {published data only}
    1. Ang MS, Abdul Rashid NA, Lee J. Impact of anticholinergic burden on cognitive performance in patients with schizophrenia. Annals of the Academy of Medicine Singapore 2015;44:S55.
Boccardi 2017 {published data only}
    1. Boccardi V, Baroni M, Paolacci L, Ercolani S, Longo A, Giordano M, et al. Anticholinergic burden and functional status in older people with cognitive impairment: results from the regal project. Journal of Nutrition, Health & Aging 2017;21(4):389-96. - PubMed
Cancelli 2009 {published data only}
    1. Cancelli I, Beltrame M, D'Anna L, Gigli GL, Valente M. Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease? Expert Opinion on Drug Safety 2009;8(5):549-57. - PubMed
Cejudo 2018 {published data only}
    1. Cejudo BM, Cuenca MC, Mora MM, MartinezFG, Sanchez CMT. Anticholinergic risk in elderly patients with dementia taking cholinesterase inhibitors. European Journal of Hospital Pharmacy 2018;25(Suppl 1):A124.
Desmarais 2012 {published data only}
    1. Desmarais JE, Margolese HC, Beauclair L, Annable L, Belanger M-C, Kolivakis TT. Discontinuing anticholinergic agents prescribed for extrapyramidal side effects in schizophrenia or schizoaffective disorder treated with antipsychotics: effects on movement disorders, cognition and psychopathology. Schizophrenia Research 2012;136:S262.
Dharia 2011 {published data only}
    1. Dharia SP, Harpe SE, Bohannon A, Slattum PW. The effect of anticholinergic burden on functional outcomes in patients with moderate to severe dementia. Clinical Pharmacology and Therapeutics 2011;89:S63.
Fortin 2009 {published data only}
    1. Fortin M-P, Rouch I, Gedeon C, Genthon S, Dauphinot V, Bonnefoy M, et al . Cognitive impact of treatment with anticholinergic properties in elderly patients consulting for memory complaint. Alzheimer's and Dementia 2009;5:339.
Gnjidic 2013 {published data only}
    1. Gnjidic D, Hilmer S, Hartikainen S, Tolppanen AM, Taipale H, Koponen M, et al. Impact of cumulative anticholinergic and sedative drug exposure on clinical outcomes in older people with and without Alzheimer's disease. Australasian Journal on Ageing 2013;32:27.
Green 2016 {published data only}
    1. Green AR, Oh E, Hilson L, Tian J, Boyd CM. Anticholinergic burden in older adults with mild cognitive impairment. Journal of the American Geriatrics Society 2016;64(12):e313-4. - PMC - PubMed
Green 2018 {published data only}
    1. Green AR, Reifler LM, Boyd CM, Weffald LA, Bayliss EA. Medication profiles of patients with cognitive impairment and high anticholinergic burden. Drugs & Aging 2018;35(3):223-32. [PMID: ] - PMC - PubMed
Green 2019 {published data only}
    1. Green AR, Reifler LM, Bayliss EA, Weffald LA, Boyd CM. Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective cohort study. Drugs & Aging 2019;36(3):289-97. - PMC - PubMed
Green 2020 {published data only}
    1. Green AR, Segal J, Boyd CM, Huang J, Roth DL. Patterns of potentially inappropriate bladder antimuscarinic use in people with dementia: a retrospective cohort study. Drugs-Real World Outcomes 2020;7(2):151-9. [PMID: ] - PMC - PubMed
Hilson 2016 {published data only}
    1. Hilson L, Tian J, Green AR. Cumulative anticholinergic burden in older adults with mild cognitive impairment. Journal of the American Geriatrics Society 2016;64:S261. - PMC - PubMed
Jewart 2005 {published data only}
    1. Jewart RD, Green J, Lu CJ, Cellar J, Tune LE. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. American Journal of Geriatric Psychiatry 2005;13(4):324-8. - PubMed
Kachru 2021 {published data only}
    1. Kachru N, Holmes HM, Johnson ML, Chen H, Aparasu RR. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. International Journal of Geriatric Psychiatry 2021;36(5):684-96. [PMID: ] - PMC - PubMed
Kidd 2014 {published data only}
    1. Kidd AC, Musonda P, Soiza RL, Butchart C, Lunt CJ, Pai Y, et al. The relationship between total anticholinergic burden (ACB) and early in-patient hospital mortality and length of stay in the oldest old aged 90 years and over admitted with an acute illness. Archives of Gerontology and Geriatrics 2014;59(1):155-61. [PMID: ] - PubMed
Kumar 2019 {published data only}
    1. Kumar S, Hasan SS, Wong PS, Chong DW, Kairuz T. Anticholinergic burden, sleep quality and health outcomes in Malaysian aged care home residents. Pharmacy 2019;7(4):143. [PMID: ] - PMC - PubMed
Lakey 2009 {published data only}
    1. Lakey SL, Odegard PS, Sonnett TE, Setter SM, Borson S. The relationship between anticholinergic medications and Mini-Cog scores in older adults receiving home health care. The Consultant Pharmacist 2009;24(9):673-80. [PMID: ] - PMC - PubMed
Landi 2007 {published data only}
    1. Landi F, Russo A, Liperoti R, Cesari M, Barillaro C, Pahor M, et al. Anticholinergic drugs and physical function among frail elderly population. Clinical Pharmacology & Therapeutics 2007;81(2):235-41. [PMID: ] - PubMed
Lattanzio 2018 {published data only}
    1. Lattanzio F, Corica F, Schepisi R, Amantea D, Bruno F, Cozza A, et al. Anticholinergic burden and 1-year mortality among older patients discharged from acute care hospital. Geriatrics & Gerontology International 2018;18(5):705-13. [PMID: ] - PubMed
MartinezArrechea 2021 {published data only}
    1. Martinez AS, Ferro UA, Beobide TI, Gonzalez BJ, Alaba TJ, Sevilla SD. Prevalence of prescription of anticholinergic/sedative burden drugs among older people with dementia living in nursing homes. Revista Espanola de Geriatria y Gerontologia 2021;56(1):11-7. - PubMed
Mate 2015 {published data only}
    1. Mate KE, Kerr KP, Pond D, Williams EJ, Marley J, Disler P, et al. Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs & Aging 2015;32(2):159-67. [PMID: ] - PubMed
Minzenberg 2004 {published data only}
    1. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. American Journal of Psychiatry 2004;161(1):116-24. [PMID: ] - PubMed
Naharci 2017 {published data only}
    1. Naharci MI, Cintosun U, Ozturk A, Oztin H, Turker T, Bozoglu E, et al. Effect of anticholinergic burden on the development of dementia in older adults with subjective cognitive decline. Psychiatry and Clinical Psychopharmacology 2017;27(3):269-76.
Oken 1994 {published data only}
    1. Oken BS, Kishiyama SS, Kaye JA, Howieson DB. Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging. Neurology 1994;44(4):657-62. [PMID: ] - PubMed
Palmer 2015 {published data only}
    1. Palmer JB, Albrecht JS, Park Y, Dutcher S, Rattinger GB, Simoni-Wastila L, et al. Use of drugs with anticholinergic properties among nursing home residents with dementia: a national analysis of Medicare beneficiaries from 2007 to 2008. Drugs & Aging 2015;32(1):79-86. [PMID: ] - PMC - PubMed
Rehse 2016 {published data only}
    1. Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophrenia Research and Treatment 2016;2016:8213165. [DOI: 10.1155/2016/8213165] [PMID: ] - DOI - PMC - PubMed
Reinold 2019 {published data only}
    1. Reinold J, Palese F, Romanese F, Logroscino G, Riedel O, Pisa FE. Anticholinergic burden before and after hospitalization in older adults with dementia: increase due to antipsychotic medications. International Journal of Geriatric Psychiatry 2019;34(6):868-80. [PMID: ] - PubMed
Roe 2002 {published data only}
    1. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. Journal of the American Geriatrics Society 2002;50(5):836-42. [PMID: ] - PubMed
Rumpel 2014 {published data only}
    1. Rumpel NR, Sinz M, Marrakchi S, Urban PP, Wohlfarth K. Critical analysis of the therapeutic use of anticholinergic effective medicines and their Impact on the incidence of hallucinations in patients with dementia. Zeitschrift fur Gerontologie und Geriatrie 2014;47:25.
Supina 2010 {published data only}
    1. Supina AL The prevalence and associated risks of concurrent use of cholinesterase inhibitors, antipsychotic and/or anticholinergic medications in patients with Alzheimer's disease. www.collectionscanada.gc.ca/obj/thesescanada/vol2/002/NR51215.PDF?oclc_n.... Calgary (AB): University of Calgary, 2010. [ISBN: 978-0-494-51215-9]
Sura 2013 {published data only}
    1. Sura SD, Carnahan RM, Chen H, Aparasu RR. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs & Aging 2013;30(10):837-44. [PMID: ] - PubMed
Sura 2014 {published data only}
    1. Sura SD, Carnahan RM, Chen H, Aparasu RR. Anticholinergic drug use and health related quality of life (HRQoL) in the elderly with dementia. Value in Health 2014;17(3):A220-1.
Swami 2016 {published data only}
    1. Swami S, Cohen RA, Kairalla JA, Manini TM. Anticholinergic drug use and risk to cognitive performance in older adults with questionable cognitive impairment: a cross-sectional analysis. Drugs & Aging 2016;33(11):809-18. [PMID: ] - PMC - PubMed
Veselinovic 2015 {published data only}
    1. Veselinovic T, Vernaleken I, Janouschek H, Kellermann T, Paulzen M, Cumming P, et al. Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology 2015;232(9):1607-17. [PMID: ] - PubMed
Williams 2019 {published data only}
    1. Williams A, Sera L, McPherson ML. Anticholinergic burden in hospice patients with dementia. American Journal of Hospice and Palliative Medicine 2019;36(3):222-7. [PMID: ] - PubMed

Additional references

CMA 2013 [Computer program]
    1. Comprehensive Meta-Analysis . Borenstein M, Hedges L, Higgins J, Rothstein H, Version 3. Englewood (NJ): Biostat Inc. , 2013. Available from www.meta-analysis.com/.
Covidence [Computer program]
    1. Covidence. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.
Cross 2016
    1. Cross AJ, George J, Woodward MC, Ames D, Brodaty H, Ilomaki J, et al. Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in Australia. Drugs & Aging 2016;33(1):37-44. - PubMed
Folstein 1975
    1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98. - PubMed
Francis 1999
    1. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry 1999;66(2):137-47. - PMC - PubMed
Geersing 2012
    1. Geersing GJ, Bouwmeester W, ZuithoF P, Spijker R, Leeflang M, Moons KG. Search filters for finding prognostic and diagnostic prediction studies in MEDLINE to enhance systematic reviews. PLoS One 2012;7:e32844. - PMC - PubMed
Hayden 2012
    1. Hayden JA, Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Annals of International Medicine 2012;158(4):280-6. - PubMed
Herrmann 2007
    1. Herrmann N, Gauthier S, Lysy PG. Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's & Dementia 2007;3(4):385-97. [PMID: ] - PubMed
Higgins 2019
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6. - PMC - PubMed
Hilmer 2018
    1. Hilmer SN. Calculating and using the drug burden index score in research and practice. Expert Review of Clinical Pharmacology 2018;11(11):1053-5. [PMID: 10.1080/17512433.2018.1528145] - DOI - PubMed
Huguet 2013
    1. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews 2013;2:71. - PMC - PubMed
Iorio 2015
    1. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870. - PubMed
Jaïdi 2018
    1. Jaïdi Y, Nonnonhou V, Kanagaratnam L, Bertholon LA, Badr S, Noël V, et al. Reduction of the anticholinergic burden makes it possible to decrease behavioral and psychological symptoms of dementia. American Journal of Geriatric Psychiatry 2018;26(3):280-8. [PMID: ] - PubMed
Jaïdi 2019
    1. Jaïdi Y, Guilloteau A, Nonnonhou V, Bertholon LA, Badr S, Morrone I, et al. Threshold for a reduction in anticholinergic burden to decrease behavioral and psychological symptoms of dementia. Journal of the American Medical Directors Association 2019;20(2):159-64. [PMID: ] - PubMed
Mayer 2015
    1. Mayer T, Haefeli WE, Seidling HM. Different methods, different results—how do available methods link a patient’s anticholinergic load with adverse outcomes? European Journal of Clinical Pharmacology 2015;71(11):1299–314. [DOI: 10.1007/s00228-015-1932-x] - DOI - PubMed
McKeith 2005
    1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72. - PubMed
McKhann 1984
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. - PubMed
McKhann 2001
    1. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work group on frontotemporal dementia and Pick's disease. Archives of Neurology 2001;58:1803-9. - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer's & Dementia 2011;7:263-9. - PMC - PubMed
Nasreddine 2005
    1. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatric Society 2005;53:695-9. - PubMed
Peat 2014
    1. Peat G, Riley RD, Croft P, Morley KI, Kyzas PA, Moons KG, et al, PROGRESS Group . Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. PLoS Medicine 2014;11(7):e1001671. - PMC - PubMed
Petersen 2001
    1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality standards subcommittee of the American academy of neurology. Neurology 2001;56:1133-42. - PubMed
Prince 2016
    1. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. Improving healthcare for people living with dementia: coverage, quality and costs now and in the future. www.alzint.org/resource/world-alzheimer-report-2016/ (accessed prior to 27 April 2021).
Riley 2019
    1. Riley RD, Moons KG, Snell KI, Ensor J, HooK L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ 2019;30:k4597. - PubMed
Román 1993
    1. Román GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43:250-60. - PubMed
Salahudeen 2016
    1. Salahudeen MS, Chyou T-Y, Nishtala PS. Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS One 2016;11(3):e0151084. [DOI: 10.1371/ journal.pone.0151084] - PMC - PubMed
Schardt 2007
    1. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Medical Informatics and Decision Making 2007;15:7-16. - PMC - PubMed
Soto 2012
    1. Soto ME, Andrieu S, Villars H, Secher M, Gardette V, Coley N, et al. Improving care of older adults with dementia: description of 6299 hospitalizations over 11 years in a special acute care unit. Journal of the American Directors Association 2012;13(5):486.e1-6. - PubMed
Steinberg 2008
    1. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al, Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County study. International Journal of Geriatric Psychiatry 2008;23:170-7. - PMC - PubMed
Taylor‐Rowan 2021
    1. Taylor-Rowan M, Edwards S, Noel-Storr AH, McCleery J, Myint PK, Soiza R, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No: CD013540. [DOI: 10.1002/14651858.CD013540.pub2] - DOI - PMC - PubMed
Tune 1999
    1. Tune LE, Egeli S. Acetylcholine and delirium. Dementia and Geriatric Cognitive Disorders 1999;10(5):342-4. - PubMed
Vaughan 2019
    1. Vaughan RM, Flynn R, Greene N. Anticholinergic burden of patients with dementia attending a Psychiatry of Later Life service. Irish Journal of Psychological Medicine 2019 May 21 [Epub ahead of print]. [DOI: 10.1017/ipm.2019.20] - DOI - PubMed
Wang 2021
    1. Wang K, Alan J, Page AT, Dimopolous E, Etherton-Beer C. Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review. Maturitas 2021;151:1-14. - PubMed

Publication types

Substances